Samsung eyes manufacturing expansions into U.S. and beyond as work on Korean 'Super Plant' plows ahead

Samsung Biologics was among a handful of manufacturers to enjoy a production boost during the COVID-19 pandemic. Now, as work on a "Super Plant" in its native South Korea progresses, the CDMO is drawing up plans for expansions in other countries, too.

The $2 billion “Super Plant” in Incheon, South Korea, will nearly double the company’s overall capacity, but it’s not stopping there, new CEO John Rim said at the virtual J.P. Morgan Healthcare Conference last week, as Samsung eyes manufacturing pushes into the U.S., then Europe and eventually, China.